HMGCR and acute myeloid leukemia: Aberrant cholesterol metabolism is a characteristic feature of AML cells and has been exploited for therapeutic interventions with statins as inhibitors of HMG-CoA reductase, the key enzyme in the MVA-cholesterol pathway[26,46,52].